The Pharmaceutical Journal Vol 267 No 7174 710-713
17 November 2001

This page
Reprint
Photocopy

  The industry
  Community pharmacy
  CPD
  Pharmacy education
  Pharmacy recruitment
  Konakion
  Prescription charge
  Communication
  The Society
  The Journal
  Onlooker

Letters to the Editor

Konakion

Product licence change

From Mr A. T. Evans, MRPharmS, and Mr M. C. L. Skerratt, MRPharmS

Roche has recently changed the product licence on Konakion 1mg/0.5ml injection. It can no longer be administered intravenously to adults. This leaves Konakion MM injection 10mg/ml for the treatment of warfarin over-anticoagulation, doses for which may be as low as 0.5–2mg (0.05–0.2ml) iv stat (British Society for Hematology). Such small volumes from a 1ml ampoule increases the risk of drug errors. Pharmacists have a responsibility to prevent drug errors occurring. This latest change in product licence does the exact opposite, and may lead to an increased risk of drug errors occurring.

We would be delighted to hear from any colleagues who may have addressed and subsequently resolved this issue.

Anthony Evans
Clinical Pharmacist

Michael Skerratt
Senior Clinical Pharmacist
Queen Elizabeth The Queen Mother Hospital,
Margate,
Kent
CT9 4AN

Back to Top

Previous Topic (Pharmacy recruitment)
Next Topic (Prescription charge)
Send your letter to The Editor